

POINT TRIAL

PROTOCOL AMENDMENT 6.0 SIGNATURE PAGE

STUDY TITLE: Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT)


DATE: April 4, 2016

We, the undersigned members of the POINT Trial Executive Committee,
have read and approve the protocol specified above and agree on its content:



S. Claiborne Johnston, MD, PhD (Chair)

Principal Investigator
University of Texas, Austin




J. Donald Easton, MD

Co-Principal Investigator
University of California, San Francisco




Anthony Kim, MD, MAS

Co-Principal Investigator
University of California, San Francisco




Mary Farrant, MBA

Clinical Coordinating Center Director
University of California, San Francisco



Anne Lindblad, PhD
CRC Director
POINT - CRC

Digitally signed by Anne S Lindblad
DN: CN=Anne S Lindblad, C=US,
O=The EMMES Corporation,
E=alindblad@emmes.com
Reason: I am the author of this
document
Location:
Date: 2016.04.05 17:02:58



William Barsan, MD

NETT Principal Investigator
University of Michigan, Ann Arbor



Lewis Morgenstern, MD

NETT Neurology Director
University of Michigan, Ann Arbor

POINT TRIAL

PROTOCOL AMENDMENT 6.0 SIGNATURE PAGE




Robin Conwit, MD
NETT Project Officer
NINDS



Yuko Palesch, PhD
NETT SDMU Co-Investigator
NETT, Medical University of South Carolina



Jordan Elm, PhD
NETT SDMU Principal Investigator
NETT, Medical University of South Carolina



Catherine Dillon, CCRP
Program Manager
NETT, Medical University of South Carolina